Cancer-specific targeting of a conditionally replicative adenovirus using mRNA translational control
Authors:
- 17 May 2007
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 108 (1) , 43-55
Abstract
Background In view of the limited success of available treatment modalities for a wide array of cancer, alternative and complementary therapeutic strategies need to be developed. Virotherapy employing conditionally replicative adenoviruses (CRAds) represents a promising targeted intervention relevant to a wide array of neoplastic diseases. Critical to the realization of an acceptable therapeutic index using virotherapy in clinical trials is the achievement of oncolytic replication in tumor cells, while avoiding non-specific replication in normal tissues. In this report, we exploited cancer-specific control of mRNA translation initiation in order to achieve enhanced replicative specificity of CRAd virotherapy agents. Heretofore, the achievement of replicative specificity of CRAd agents has been accomplished either by viral genome deletions or incorporation of tumor selective promoters. In contrast, control of mRNA translation has not been exploited for the design of tumor specific replicating viruses to date. We show herein, the utility of a novel approach that combines both transcriptional and translational regulation strategies for the key goal of replicative specificity. Methods We describe the construction of a CRAd with cancer specific gene transcriptional control using the CXCR4 gene promoter (TSP) and cancer specific mRNA translational control using a 5′-untranslated region (5′-UTR) element from the FGF-2 (Fibroblast Growth Factor-2) mRNA. Results Both in vitro and in vivo studies demonstrated that our CRAd agent retains anti-tumor potency. Importantly, assessment of replicative specificity using stringent tumor and non-tumor tissue slice systems demonstrated significant improvement in tumor selectivity. Conclusions Our study addresses a conceptually new paradigm: dual targeting of transgene expression to cancer cells using both transcriptional and mRNA translational control. Our novel approach addresses the key issue of replicative specificity and can potentially be generalized to a wide array of tumor types, whereby tumor selective patterns of gene expression and mRNA translational control can be exploited.Keywords
This publication has 45 references indexed in Scilit:
- Employment of liver tissue slice analysis to assay hepatotoxicity linked to replicative and nonreplicative adenoviral agentsCancer Gene Therapy, 2006
- Oncolytic adenoviruses – selective retargeting to tumor cellsOncogene, 2005
- Keloid fibroblast responsiveness to epidermal growth factor and activation of downstream intracellular signaling pathwaysWound Repair and Regeneration, 2004
- Transcriptional targeting of adenoviral vector through the CXCR4 tumor-specific promoterGene Therapy, 2004
- Transcriptional targeting of tumors with a novel tumor-specific survivin promoterCancer Gene Therapy, 2004
- A molecular signature of metastasis in primary solid tumorsNature Genetics, 2002
- Adenoviral Vectors Stimulate Murine Natural Killer Cell Responses and Demonstrate Antitumor Activities in the Absence of Transgene ExpressionMolecular Therapy, 2002
- Intratumoral Administration of Low Doses of an Adenovirus Vector Encoding Tumor Necrosis Factor α Together with Naive Dendritic Cells Elicits Significant Suppression of Tumor Growth without ToxicityHuman Gene Therapy, 2001
- Elevated levels of eukaryotic translation initiation factor eIF-4E, mRNA in a broad spectrum of transformed cell linesCancer Letters, 1995
- The involvement of mRNA secondary structure in protein synthesisBiochemistry and Cell Biology, 1987